2
Clinical Trials associated with CR-059 / RecruitingEarly Phase 1IIT A Single-Center, Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus
Primary Objectives:
•To evaluate the safety and tolerability of a single dose of Exenatide Circular RNA-Lipid Nanoparticle Injection(CR059)in Chinese subjects with T2DM.
Secondary Objectives:
* To characterize the pharmacokinetic (PK) profile of a single dose of Exenatide Circular RNA-Lipid Nanoparticle Injection(CR059) in Chinese subjects with T2DM;
* To characterize the pharmacodynamic (PD) profile of a single dose of Exenatide Circular RNA-Lipid Nanoparticle Injection( CR059) in Chinese subjects with T2DM;
* To evaluate the immunogenicity of a single dose of Exenatide Circular RNA-Lipid Nanoparticle Injection( CR059) in Chinese subjects with T2DM;
Participants :
Diagnosed with T2DM for at least 3 months but less than 5 years, according to the Chinese Diabetes Society's diagnostic criteria
/ Not yet recruitingEarly Phase 1IIT A Single-Center, Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects with Type 2 Diabetes Mellitus
Start Date01 Dec 2025 |
Sponsor / Collaborator- |
100 Clinical Results associated with CR-059
100 Translational Medicine associated with CR-059
100 Patents (Medical) associated with CR-059
100 Deals associated with CR-059